114 related articles for article (PubMed ID: 8694822)
21. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
22. Soluble urokinase receptor from fibrosarcoma HT-1080 cells.
Lau HK; Kim M
Blood Coagul Fibrinolysis; 1994 Aug; 5(4):473-8. PubMed ID: 7841301
[TBL] [Abstract][Full Text] [Related]
23. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage.
Wohn KD; Kanse SM; Deutsch V; Schmidt T; Eldor A; Preissner KT
Thromb Haemost; 1997 Mar; 77(3):540-7. PubMed ID: 9066008
[TBL] [Abstract][Full Text] [Related]
24. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
[TBL] [Abstract][Full Text] [Related]
25. [Urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in the seminal plasma and sperm of fertile and oligoasthenozoospermia males].
Wang L; Guan HT; Tian YH; Xiong CL
Zhonghua Nan Ke Xue; 2006 Sep; 12(9):791-3. PubMed ID: 17009528
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-type plasminogen activator.
Crippa MP
Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
[TBL] [Abstract][Full Text] [Related]
27. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
28. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
29. Basal release of urokinase plasminogen activator, plasminogen activator inhibitor-1, and soluble plasminogen activator receptor from separated and cultured endometriotic and endometrial stromal and epithelial cells.
Bruse C; Guan Y; Carlberg M; Carlström K; Bergqvist A
Fertil Steril; 2005 Apr; 83 Suppl 1():1155-60. PubMed ID: 15831288
[TBL] [Abstract][Full Text] [Related]
30. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.
Zanetti A; Stoppacciaro A; Marzullo A; Ciabatta M; Fazioli F; Prat M; Comoglio PM; Baroni CD; Ruco LP
J Pathol; 1998 Nov; 186(3):287-91. PubMed ID: 10211118
[TBL] [Abstract][Full Text] [Related]
31. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
32. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
[TBL] [Abstract][Full Text] [Related]
33. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
[TBL] [Abstract][Full Text] [Related]
34. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Al-Ejeh F; Croucher D; Ranson M
Exp Cell Res; 2004 Jul; 297(1):259-71. PubMed ID: 15194441
[TBL] [Abstract][Full Text] [Related]
35. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
36. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
37. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.
Boyd D; Florent G; Kim P; Brattain M
Cancer Res; 1988 Jun; 48(11):3112-6. PubMed ID: 2835152
[TBL] [Abstract][Full Text] [Related]
38. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells.
Miles LA; Plow EF
Thromb Haemost; 1987 Oct; 58(3):936-42. PubMed ID: 2829380
[TBL] [Abstract][Full Text] [Related]
39. Cellular receptor for urokinase-type plasminogen activator: protein structure.
Behrendt N; Ploug M; Rønne E; Høyer-Hansen G; Danø K
Methods Enzymol; 1993; 223():207-22. PubMed ID: 8271954
[No Abstract] [Full Text] [Related]
40. A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking.
Behrendt N; Rønne E; Danø K
FEBS Lett; 1993 Dec; 336(3):394-6. PubMed ID: 7904248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
